 AIM ImmunoTech Inc NYSE:AIM said it will add two directors to its board to bring diversity and additional biotechnology commercialization experience. AIM ImmunoTech also said its board compensation committee will engage an independent compensation consultant to evaluate the compensation plans currently in place for company executives. 